Navigation Links
Creatine Has Negligible Effect on COPD Exercise Rehab
Date:8/1/2008

Popular nutritional supplement no substitute for old-fashioned hard work, study says

FRIDAY, Aug. 1 (HealthDay News) -- Taking creatine doesn't improve exercise outcomes in people who have chronic obstructive pulmonary disease (COPD), a U.K. study reports.

Creatine is a popular nutritional supplement used to enhance athletic performance and muscle strength. This study included 100 COPD patients who received either creatine or a placebo during a seven-week pulmonary rehabilitation program.

Of the 80 patients who completed the study, there were no differences in muscle strength between those who took creatine and those who got the placebo. Any benefits of creatine may have been overshadowed by the effects of physical training, the researchers suggested.

"We have evidence to suggest Cr [creatine] uptake into muscles (in COPD patients), but are unable to explain why an increase in muscle Cr did not enhance training," wrote study lead author Dr. Sarah Deacon, specialist registrar at the Institute for Lung Health at Glenfield Hospital in Leicester, England.

The study was published in the first August issue of the American Journal of Respiratory and Critical Care Medicine.

The findings suggest there's no substitute for the hard physical work that's an essential component of pulmonary rehabilitation.

"Those of us interested in pulmonary rehabilitation are happy to see confirmation of the beneficial effects of exercise training. This information indicates that creatine supplementation not be viewed as a substitute for exercise training," wrote Dr. Francoise Maltais and colleagues at the Centre de Recherche de l'Hospital Laval in Quebec, Canada.

More information

The American Academy of Family Physicians has more about COPD.

'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. No substitute for hard work: Creatine supplementation does not improve exercise outcomes in COPD
2. Creatine in addition to exercise enhances strength in older adults
3. BCBSA: Time Is Right for Comparative Effectiveness Research Institute
4. PCMA Statement on Baucus-Conrad Comparative Effectiveness Legislation
5. American Academy of Dermatology: Acne and Rosacea Got You Seeing Red? Patients with Skin of Color Advised to Seek Proper Diagnosis, Treatment to Prevent Common Side Effects
6. 2 different breast cancer screening strategies are equally effective
7. 2 Breast Cancer Screening Strategies Prove Effective
8. Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report
9. Survey: Most effective dental braces are least attractive
10. Study Measures Real-World Comparative Effectiveness of Asthma Controller Medications
11. New Report Examines Pharmaceutical Sales Force Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 1Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 2Menopause Is More Than A Hot Flash 51759 1Menopause Is More Than A Hot Flash 51759 2Menopause Is More Than A Hot Flash 51759 3Menopause Is More Than A Hot Flash 51759 4Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 1Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 2Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 3